Disease Info Card

Biliary Tract Cancer

Information about Biliary Tract Cancer: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Biliary Tract Cancer

Most recent studies have shown that Biliary Tract Cancer shares some biological mechanisms with adenocarcinoma, bile-duct-carcinoma, bile-duct-neoplasms, biliary-tract-neoplasm, carcinoma, cholangiocarcinoma, cholangitis, cholecystolithiasis, cholelithiasis, gall-bladder-diseases, gallbladder-neoplasm, icterus, liver-neoplasms, malignant-neoplasm-of-gallbladder, malignant-neoplasm-of-pancreas, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasm-metastasis, neoplasms, pancreatic-neoplasm.

Among the many pathways, these few ones have gauged particular interests from scientists studying Biliary Tract Cancer, and have been seen in publications frequently: Cell Adhesion, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Growth, Cell Proliferation, Dna Repair, Excretion, Gene Silencing, Induction Of Apoptosis, Liver Regeneration, Localization, Menarche, Methylation, Mismatch Repair, Pathogenesis, Pigmentation, Regeneration, Response To Gemcitabine, Transport

Quite a number of genes have been found to play important roles in Biliary Tract Cancer, such as BTC, CDKN2A, CEACAM5, CEACAM7, EGFR, ERBB2, GEM, GMNN, HRAS, IL6, MID1, MLH1, MSH2, PGR, PSG2, SMAD4, TMEM37, TP53. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.